Compare · ABSI vs SYNH
ABSI vs SYNH
Side-by-side comparison of Absci Corporation (ABSI) and Syneos Health Inc. (SYNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and SYNH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- SYNH is the larger of the two at $9.19B, about 9.0x ABSI ($1.02B).
- ABSI has hit the wire 10 times in the past 4 weeks while SYNH has been quiet.
- ABSI has more recent analyst coverage (21 ratings vs 19 for SYNH).
- Company
- Absci Corporation
- Syneos Health Inc.
- Price
- $6.66+1.76%
- $42.98+0.01%
- Market cap
- $1.02B
- $9.19B
- 1M return
- +12.89%
- -
- 1Y return
- +124.83%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2014
- News (4w)
- 10
- 0
- Recent ratings
- 21
- 19
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Syneos Health Inc.
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina
Latest ABSI
- Director Szela Mary T was granted 10,100 shares (SEC Form 4)
- Director Pangalos Menelas N was granted 10,100 shares, increasing direct ownership by 4% to 242,408 units (SEC Form 4)
- Director Van Houten Frans was granted 10,100 shares, increasing direct ownership by 16% to 73,420 units (SEC Form 4)
- Director Rabinovitsj Daniel A was granted 10,100 shares, increasing direct ownership by 43% to 33,420 units (SEC Form 4)
- Director Sirosh Joseph was granted 10,100 shares, increasing direct ownership by 43% to 33,420 units (SEC Form 4)
- Absci Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Leerink Partners initiated coverage on Absci Corporation with a new price target
- CFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,319 shares, decreasing direct ownership by 2% to 491,464 units (SEC Form 4) to satisfy withholding tax
- BTIG Research initiated coverage on Absci Corporation with a new price target
- Absci to Participate in Upcoming Investor Conferences
Latest SYNH
- Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.
- Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting
- Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)
- NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers
- SEC Form 15-12G filed by Syneos Health Inc.
- Syneos Health Tapped PRA Health Sciences' Colin Shannon as the CEO Succeeding Michelle Keefe
- SEC Form 8-K filed by Syneos Health Inc.
- Zulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)
- Wilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)
- Monaghan Matthew E. returned $850,411 worth of shares to the company (24,640 units at $34.51), closing all direct ownership in the company (SEC Form 4)